Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311

C1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into clinical trial. The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase II. In this study, cellula...

Descripción completa

Detalles Bibliográficos
Autores principales: Burger, A M, Jenkins, T C, Double, J A, Bibby, M C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362878/
https://www.ncbi.nlm.nih.gov/pubmed/10496367
http://dx.doi.org/10.1038/sj.bjc.6690702

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362878/
https://www.ncbi.nlm.nih.gov/pubmed/10496367
http://dx.doi.org/10.1038/sj.bjc.6690702

Ejemplares similares